Please login to order a test.
- GP 47680
Analysis of active metabolite, 10-hydroxy carbamazepine (MHD)
Oxcarbazepine is an antiepileptic drug, indicated for use as monotherapy or adjunctive therapy in the treatment of partial seizures in adults with epilepsy. It is used in adjunctive therapy in epileptic children between the ages of four and 16.
Clinically significant hyponatremia (sodium <125 mmol/L) can develop during oxcarbazepine use. This generally occurs during the first three months of treatment.
This test was developed and its performance characteristics determined by LabCorp. It has not been cleared or approved by the Food and Drug Administration.
Liquid chromatography/tandem mass spectrometry (LC/MS-MS)
Oxcarbazepine is the prodrug for its active metabolite, 10-hydroxy-carbamazepine (MHD). MHD reaches maximal serum concentrations in three to five hours after oral ingestion and is 40% bound to protein. The elimination half-life is 8 to 15 hours.1 Co-administration of other antiepileptic drugs (eg, carbamazepine, phenytoin, phenobarbital, primidone) causes decreases in MHD serum levels.2
Serum or plasma
Red-top tube or plastic transport tube. Do not use a gel-barrier tube. The use of gel-barrier tubes is not recommended due to slow absorption of the drug by the gel. Depending on the specimen volume and storage time, the decrease in drug level due to absorption may be clinically significant.
Transfer separated serum or plasma to a plastic transport tube. Draw trough levels immediately prior to next dose. Steady-state levels are reached within two to three days in patients taking oxcarbazepine twice daily.
Causes for Rejection
Gross lipemia; hemolysis; icteric specimen; gel-barrier tube
|Order Code||Order Code Name||Order Loinc||Result Code||Result Code Name||UofM||Result LOINC|